Growth Differentiation Factor-15 Linked to Transplant-Free Survival in PH - The Cardiology Advisor

Growth Differentiation Factor-15 Linked to Transplant-Free Survival in PH - The Cardiology Advisor

Growth Differentiation Factor-15 Linked to Transplant-Free Survival in PH - The Cardiology Advisor

Posted: 25 Sep 2019 04:00 AM PDT

Growth differentiation factor-15 (GDF-15) could be a promising biomarker to identify low-risk patients with normal GDF-15 levels, potentially serving as a predictor for mortality in adults with pulmonary hypertension (PH), according to study results published in Heart.

This single-center, prospective, observational cohort study included adults diagnosed with PH at their tertiary-care center between May 2012 and October 2016 (N=103). Researchers defined diagnostic right heart catheterization as the baseline and defined PH as a mean pulmonary artery pressure ≥25 mm Hg. To assess the biomarker, they sampled venous blood during the diagnostic right heart catheterization for study purposes only. Investigators used an electrochemiluminescence assay to directly measure N-terminal prohormone of brain natriuretic peptide (NT-proBNP) and GDF-15.

Growth differentiation factor-15 was elevated in 74% (n=76/103) of patients. It showed a significant moderate correlation with NT-proBNP (r =0.51, P <.001) and estimated glomerular filtration rate (r =−0.47, P <.001). Median follow-up was 3.4 years (interquartile range, 2.3-4.6). The primary endpoint of all-cause mortality or lung transplantation was reached in 31.1% of patients (n=32). The secondary endpoint, a composite that included the primary endpoint and heart failure, was reached in 39.8% (n=41) of patients. Causes of death in the 30 patients who died were end-stage heart failure (n=9), sudden death presumed cardiac (n=4), multiorgan failure (n=3), other diverse causes (n=13), and unknown cause (n=1).

Patients who had normal GDF-15 had a significantly higher transplant-free survival compared with patients with elevated GDF-15 (P =.007), which was specifically pronounced within the first 2 years of follow-up.

After adjusting for several clinical characteristics as well as age and NT-proBNP, GDF-15 was significantly associated with the primary endpoint.

The limitations of this study included the exclusion of patients with PH caused by left heart disease, which should be considered when extrapolating these results to other studies. This study consisted of a heterogeneous group of PH etiologies, so subgroup analysis could only be performed for pulmonary arterial hypertension. The clinical usefulness of GDF-15 might differ among PH etiologies. Because of limited statistical power, the additive value of GDF-15 could not be assessed.

Growth differentiation factor-15 was strongly associated with mortality in this study and specifically identified low-risk patients with PH at the time of diagnosis.

Related Articles

Measuring GDF-15 could be considered as a means to identify and reassure newly diagnosed patients with PH. Follow-up frequency can probably be lowered in these patients compared with patients at high risk.

More research is needed to validate these findings before integrating them into clinical practice and to further explore the potential of GDF-15 as a biomarker for predicting mortality.

Reference

Geenen LW, Baggen VJM, Kauling RM, et al. Growth differentiation factor-15 as candidate predictor for mortality in adults with pulmonary hypertension [published online September 6, 2019]. Heart. doi:10.1136/heartjnl-2019-315111

Topics:

Pulmonary Hypertension Pulmonary Vasculature

Comments

Post a Comment

Popular posts from this blog

Novitium's Generic Sildenafil for PAH Treatment Approved by FDA - Pulmonary Hypertension News

Image
Novitium&#039;s Generic Sildenafil for PAH Treatment Approved by FDA - Pulmonary Hypertension News Novitium&#039;s Generic Sildenafil for PAH Treatment Approved by FDA - Pulmonary Hypertension News Growing Doubt, Uncertainty Over PDE5i Use in Left Heart Disease - Medscape AnMed Health gains national recognition through the Pulmonary Hypertension Association - WSPA.com Novitium&#039;s Generic Sildenafil for PAH Treatment Approved by FDA - Pulmonary Hypertension News Posted: 12 Jun 2019 05:00 AM PDT The U.S. Food and Drug Administration (FDA) has approved Novitium Pharma 's generic sildenafil for oral suspension at a dose of 10 mg/mL for the treatment of pulmonary arterial hypertension (PAH). This product, which had been designated a competitive generic therapy by the FDA, is the first approved generic equivalent to Pfizer 's Revatio , a vasodilator agent that induces blood ves
Read more

Epoprostenol Via High-Flow Nasal Cannula Improves Severe Hypoxemia in PH - Pulmonology Advisor

Image
Epoprostenol Via High-Flow Nasal Cannula Improves Severe Hypoxemia in PH - Pulmonology Advisor Epoprostenol Via High-Flow Nasal Cannula Improves Severe Hypoxemia in PH - Pulmonology Advisor Posted: 11 Jul 2019 12:00 AM PDT For patients with severe hypoxemia with pulmonary hypertension or right heart dysfunction, inhaled epoprostenol through high-flow nasal cannula increases oxygenation, according to a study published in Pharmaceutics . The researchers of this retrospective study assessed the effect of inhaled epoprostenol using a high-flow nasal cannula on oxygenation and future mechanical ventilation in patients with hypoxemia comorbid with pulmonary hypertension or right heart dysfunction in an intensive care unit setting. A chart review was completed on adult patients who were admitted into the respiratory care department of the Rush University Medical Center for severe hypoxemia between July 2015 and April 2018 and treated with inha
Read more

Analysis: Large pharma companies do little new drug innovation - STAT

Image
Analysis: Large pharma companies do little new drug innovation - STAT Analysis: Large pharma companies do little new drug innovation - STAT Gene Therapy Takes Center Stage at 2019 NORD Summit - Pulmonary Hypertension News People Living With Type 2 Diabetes Want Information and Empathy From Their Doctors More Than New Medications - PRNewswire Analysis: Large pharma companies do little new drug innovation - STAT Posted: 10 Dec 2019 01:51 AM PST L arge pharmaceutical companies oppose legislation being considered by Congress to lower the prices of prescription drugs. Reducing their revenues, they contend, will reduce their investment in drug development and the discovery of new medicines, and thus lead to a decline in drug innovation. If that argument is credible, there should be evidence to show that the large pharmaceutical companies are responsible for discovering innovative new drugs. To test that claim, we examined the
Read more